Brise Pharmaceuticals Raises $20 Million for Pain Treatment Development

Brise Pharmaceuticals' Pre-A and Pre-A+ Financing

Key Highlights:

• Pre-A and Pre-A+ Financing: Brise Pharmaceuticals, a Shanghai-based company specializing in pain treatments, completed approximately $20 million in Pre-A and Pre-A+ financing.
• Investors: Shunxi Fund, Cnfuel Capital, Vinner Therapeutics, Qiming Venture Partners, BioTrack Capital, and Sherpa Healthcare Partners participated in the funding rounds.
• Product Pipeline: Funds will be used to advance Brise's product pipeline in preclinical and clinical stages, focusing on innovative analgesic treatments for migraine, neuropathic, and musculoskeletal pain.

Brise Pharmaceuticals' Target Market

• Target Market: Patients suffering from acute and chronic pain conditions, particularly those with migraine, neuropathic, and musculoskeletal pain.
• Healthcare Providers and Specialists: Pain management specialists, neurologists, and other healthcare professionals treating patients with debilitating pain conditions.
• Pharmaceutical Companies and Research Institutions: Collaborations with pharmaceutical companies and research institutions for drug development and clinical trials.

What Brise Pharmaceuticals Needs to Buy

• Research and Development Services: Partnerships with research organizations and contract research organizations (CROs) for preclinical and clinical development of pain treatments.
• Manufacturing and Supply Chain Solutions: Collaborations with manufacturers for the production and distribution of pain medications.
• Regulatory and Compliance Expertise: Engaging with regulatory consultants and experts to navigate the complex landscape of drug development and approvals.